Suven Life Sciences
SUVEN · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti Listing date: Oct. 23, 2003 · Employees: 130 · Hyderabad · http://www.suven.com

Stock Price vs Company Growth
1d
7.9%
1w
34.1%
1m
50.6%
3m
48.5%
6m
52.9%
1y
83.8%
5y
38.5%
10y
3.8%
all
10.6%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowSep07Mar11Sep14Mar18Sep21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

184 7.9%
103
188
Company Overview

Sales
6.66 Cr
Growth: -0.6%
Profit after Tax
-161 Cr
Growth: 12.1%
Small Cap
4,020 Cr
P/S: 604.0x
Industry P/S: 2.9x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 6.66
Growth -0.6%
EBITDA -2490.6%
P/S 604.0x
Dividend 0.0%
P/E -25.0x
Book Value ₹ 5.04
PEG Ratio 44.8x
ROE -92.2%
P/B 36.6x
Shareholding Pattern

Institutions
Rambabu Chirumamilla
1.56 %
Iepf
0.14 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Jun21Sep21Mar22Sep22
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Jun21Sep21Mar22Sep22
Others
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Jun21Sep21Mar22Sep22
Increase    Decrease    No change
Company Profile Detailed

Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.
Investors (36)
Followers (7)